Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

The Adolescent with Menorrhagia: Diagnostic Approach to a Suspected Bleeding Disorder.

Graham RA, Davis JA, Corrales-Medina FF.

Pediatr Rev. 2018 Dec;39(12):588-600. doi: 10.1542/pir.2017-0105. No abstract available.

PMID:
30504251
2.

Perceptions of Resilience and Physical Health Symptom Improvement Following Post Disaster Integrated Health Services.

Osofsky HJ, Weems CF, Graham RA, Osofsky JD, Hansel TC, King LS.

Disaster Med Public Health Prep. 2018 Jun 19:1-7. doi: 10.1017/dmp.2018.35. [Epub ahead of print]

PMID:
29916794
3.

Cap-assisted necrosectomy: a novel technique increasing safety and efficiency.

Puri N, Graham RA.

VideoGIE. 2017 Jul 19;2(10):260-261. doi: 10.1016/j.vgie.2017.06.003. eCollection 2017 Oct. No abstract available.

4.

Gerbode defect: A comprehensive review of its history, anatomy, embryology, pathophysiology, diagnosis, and treatment.

Saker E, Bahri GN, Montalbano MJ, Johal J, Graham RA, Tardieu GG, Loukas M, Tubbs RS.

J Saudi Heart Assoc. 2017 Oct;29(4):283-292. doi: 10.1016/j.jsha.2017.01.006. Epub 2017 Feb 16. Review.

5.
6.

Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index.

Anderson PG, Kalli S, Sassaroli A, Krishnamurthy N, Makim SS, Graham RA, Fantini S.

Acad Radiol. 2017 Oct;24(10):1240-1255. doi: 10.1016/j.acra.2017.03.020. Epub 2017 May 19.

7.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.

8.
9.

Parenting Behaviors, Parent Heart Rate Variability, and Their Associations with Adolescent Heart Rate Variability.

Graham RA, Scott BG, Weems CF.

J Youth Adolesc. 2017 May;46(5):1089-1103. doi: 10.1007/s10964-016-0616-x. Epub 2016 Nov 30.

PMID:
27904984
10.

Surgical relevance of the lateral costotransverse ligament in relation to the dorsal root ganglion.

D'Antoni AV, Collin PG, Graham RA, Kennedy HM, Ndjatou T, Perez P, Tubbs RS, Loukas M, Kozlowski PB, Mtui EP.

Anat Sci Int. 2018 Jan;93(1):108-113. doi: 10.1007/s12565-016-0381-7. Epub 2016 Nov 9.

PMID:
27830440
11.

Agreement in Youth-Parent Perceptions of Parenting Behaviors: A Case for Testing Measurement Invariance in Reporter Discrepancy Research.

Russell JD, Graham RA, Neill EL, Weems CF.

J Youth Adolesc. 2016 Oct;45(10):2094-107. doi: 10.1007/s10964-016-0495-1. Epub 2016 Jun 11.

PMID:
27289553
12.

A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.

Malhi V, Colburn D, Williams SJ, Hop CE, Dresser MJ, Chandra P, Graham RA.

Cancer Chemother Pharmacol. 2016 Jul;78(1):41-9. doi: 10.1007/s00280-016-3020-z. Epub 2016 May 6.

13.

Optical mammography: bilateral breast symmetry in hemoglobin saturation maps.

Anderson PG, Sassaroli A, Kainerstorfer JM, Krishnamurthy N, Kalli S, Makim SS, Graham RA, Fantini S.

J Biomed Opt. 2016 Oct;21(10):101403. doi: 10.1117/1.JBO.21.10.101403.

14.

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.

Lu D, Lu T, Stroh M, Graham RA, Agarwal P, Musib L, Li CC, Lum BL, Joshi A.

Cancer Chemother Pharmacol. 2016 Mar;77(3):459-76. doi: 10.1007/s00280-015-2931-4. Epub 2016 Jan 25. Review.

15.

Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib.

Lu T, Wang B, Gao Y, Dresser M, Graham RA, Jin JY.

CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):680-9. doi: 10.1002/psp4.12039. Epub 2015 Nov 9.

16.

Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.

Rudek MA, Graham RA, Ratain MJ.

J Clin Oncol. 2016 Jan 10;34(2):103-4. doi: 10.1200/JCO.2015.64.2553. Epub 2015 Nov 30. No abstract available.

17.

Broadband optical mammography: chromophore concentration and hemoglobin saturation contrast in breast cancer.

Anderson PG, Kainerstorfer JM, Sassaroli A, Krishnamurthy N, Homer MJ, Graham RA, Fantini S.

PLoS One. 2015 Mar 17;10(3):e0117322. doi: 10.1371/journal.pone.0117322. eCollection 2015.

18.

Identity Distress among Youth Exposed to Natural Disasters: Associations with Level of Exposure, Posttraumatic Stress, and Internalizing Problems.

Scott BG, Sanders AF, Graham RA, Banks DM, Russell JD, Berman SL, Weems CF.

Identity (Mahwah, N J). 2014 Oct 1;14(4):255-267.

19.

Developmental differences in the linkages between anxiety control beliefs and posttraumatic stress in youth.

Weems CF, Russell JD, Graham RA, Neill EL, Banks DM.

Depress Anxiety. 2015 May;32(5):356-63. doi: 10.1002/da.22319. Epub 2014 Nov 24.

PMID:
25421545
20.
21.

Memories of traumatic events in childhood fade after experiencing similar less stressful events: results from two natural experiments.

Weems CF, Russell JD, Banks DM, Graham RA, Neill EL, Scott BG.

J Exp Psychol Gen. 2014 Oct;143(5):2046-55. doi: 10.1037/xge0000016. Epub 2014 Jul 28.

PMID:
25068536
22.

Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer.

Morrison SA, Hill SL, Rogers GS, Graham RA.

J Surg Res. 2014 Dec;192(2):235-41. doi: 10.1016/j.jss.2014.06.030. Epub 2014 Jun 24.

PMID:
25043529
23.

Fitting anxious emotion-focused intervention into the ecology of schools: results from a test anxiety program evaluation.

Weems CF, Scott BG, Graham RA, Banks DM, Russell JD, Taylor LK, Cannon MF, Varela RE, Scheeringa MA, Perry AM, Marino RC.

Prev Sci. 2015 Feb;16(2):200-10. doi: 10.1007/s11121-014-0491-1.

PMID:
24810999
24.

Resilience and trajectories of posttraumatic stress among youth exposed to disaster.

Weems CF, Graham RA.

J Child Adolesc Psychopharmacol. 2014 Feb;24(1):2-8. doi: 10.1089/cap.2013.0042. Epub 2013 Nov 7.

PMID:
24200122
25.

KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.

Dai B, Yoo SY, Bartholomeusz G, Graham RA, Majidi M, Yan S, Meng J, Ji L, Coombes K, Minna JD, Fang B, Roth JA.

Cancer Res. 2013 Sep 1;73(17):5532-43. doi: 10.1158/0008-5472.CAN-13-0712. Epub 2013 Jul 3.

26.

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE.

Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3.

27.

Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.

Graham RA, Chang I, Jin JY, Wang B, Dufek MB, Ayache JA, Ezzet F, Zerivitz K, Low JA, Dresser MJ.

J Cardiovasc Pharmacol. 2013 Jan;61(1):83-9. doi: 10.1097/FJC.0b013e3182793ac9.

PMID:
23107871
28.

A modified triple test for palpable breast masses: the value of ultrasound and core needle biopsy.

Wai CJ, Al-Mubarak G, Homer MJ, Goldkamp A, Samenfeld-Specht M, Lee Y, Logvinenko T, Rothschild JG, Graham RA.

Ann Surg Oncol. 2013 Mar;20(3):850-5. doi: 10.1245/s10434-012-2710-y. Epub 2012 Oct 27.

PMID:
23104707
29.

A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.

Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA.

Clin Cancer Res. 2013 Jan 1;19(1):258-67. doi: 10.1158/1078-0432.CCR-12-1800. Epub 2012 Oct 18.

30.

Is T.V. traumatic for all youths? The role of preexisting posttraumatic-stress symptoms in the link between disaster coverage and stress.

Weems CF, Scott BG, Banks DM, Graham RA.

Psychol Sci. 2012;23(11):1293-7. doi: 10.1177/0956797612446952. Epub 2012 Oct 15.

PMID:
23070308
31.

Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.

LoRusso PM, Piha-Paul SA, Mita M, Colevas AD, Malhi V, Colburn D, Yin M, Low JA, Graham RA.

Cancer Chemother Pharmacol. 2013 Jan;71(1):193-202. doi: 10.1007/s00280-012-1996-6. Epub 2012 Oct 11.

PMID:
23064958
32.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A.

N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.

33.

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, Shin YG, Malhi V, Low JA, Dresser MJ.

Br J Clin Pharmacol. 2012 Nov;74(5):788-96. doi: 10.1111/j.1365-2125.2012.04281.x.

34.

Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.

Lorusso PM, Jimeno A, Dy G, Adjei A, Berlin J, Leichman L, Low JA, Colburn D, Chang I, Cheeti S, Jin JY, Graham RA.

Clin Cancer Res. 2011 Sep 1;17(17):5774-82. doi: 10.1158/1078-0432.CCR-11-0972. Epub 2011 Jul 13.

35.

Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.

Deng Y, Wong H, Graham RA, Liu W, Shen HS, Shi Y, Wang L, Meng M, Malhi V, Ding X, Dean B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 15;879(22):2119-26. doi: 10.1016/j.jchromb.2011.05.048. Epub 2011 Jun 12.

PMID:
21704573
36.

A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.

Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, Hop CE.

Drug Metab Dispos. 2011 Aug;39(8):1460-7. doi: 10.1124/dmd.111.039339. Epub 2011 May 20.

37.

Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).

Giannetti AM, Wong H, Dijkgraaf GJ, Dueber EC, Ortwine DF, Bravo BJ, Gould SE, Plise EG, Lum BL, Malhi V, Graham RA.

J Med Chem. 2011 Apr 28;54(8):2592-601. doi: 10.1021/jm1008924. Epub 2011 Mar 25.

PMID:
21438527
38.

Non-trocar related major retroperitoneal bleeding during laparoscopic appendectomy.

Kaafarani HM, D'Achille J, Graham RA.

World J Emerg Surg. 2011 Mar 22;6:9. doi: 10.1186/1749-7922-6-9.

39.

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD.

Clin Cancer Res. 2011 Apr 15;17(8):2502-11. doi: 10.1158/1078-0432.CCR-10-2745. Epub 2011 Feb 7.

40.

Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.

Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM.

Clin Cancer Res. 2011 Apr 15;17(8):2512-20. doi: 10.1158/1078-0432.CCR-10-2736. Epub 2011 Feb 7.

41.

Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines.

Keller PJ, Lin AF, Arendt LM, Klebba I, Jones AD, Rudnick JA, DiMeo TA, Gilmore H, Jefferson DM, Graham RA, Naber SP, Schnitt S, Kuperwasser C.

Breast Cancer Res. 2010;12(5):R87. doi: 10.1186/bcr2755. Epub 2010 Oct 21.

42.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

43.

Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry.

Ding X, Chou B, Graham RA, Cheeti S, Percey S, Matassa LC, Reuschel SA, Meng M, Liu S, Voelker T, Lum BL, Rudewicz PJ, Hop CE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):785-90. doi: 10.1016/j.jchromb.2010.01.039. Epub 2010 Feb 1.

PMID:
20172765
44.

Cloning, tissue expression, and regulation of beagle dog CYP4A genes.

Graham RA, Goodwin B, Merrihew RV, Krol WL, Lecluyse EL.

Toxicol Sci. 2006 Aug;92(2):356-67. Epub 2006 May 4.

PMID:
16675513
45.

Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes.

Graham RA, Tyler LO, Krol WL, Silver IS, Webster LO, Clark P, Chen L, Banks T, LeCluyse EL.

J Biochem Mol Toxicol. 2006;20(2):69-78.

PMID:
16615094
47.

Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 Cells.

Smith CM, Graham RA, Krol WL, Silver IS, Negishi M, Wang H, Lecluyse EL.

J Pharmacol Exp Ther. 2005 Dec;315(3):1256-64. Epub 2005 Aug 31.

48.

Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes.

Baughman TM, Graham RA, Wells-Knecht K, Silver IS, Tyler LO, Wells-Knecht M, Zhao Z.

Drug Metab Dispos. 2005 Jun;33(6):733-8. Epub 2005 Mar 11.

49.
50.

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A.

Drug Metab Dispos. 2003 Apr;31(4):421-31.

Supplemental Content

Loading ...
Support Center